Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice

Nephron - Experimental Nephrology

Volumn 104, Issue 1, 2006, Pages

  Collins, Sarah J ^a   Alexander, Shannon L ^a   Lopez Guisa, Jesus M ^a   Cai, Xiaohe ^a   Maruvada, Ravi ^a   Chua, Streamson C ^b   Zhang, Guoqiang ^a   Okamura, Daryl M ^a   Matsuo, Shunya ^a   Eddy, Allison A ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cholesterol; Diabetes; Plasminogen activator inhibitor 1; Proteinuria; Runting

Indexed keywords

ALBUMIN; CASEIN; CHOLESTEROL; COLLAGEN; CREATININE; GLUCOSE; INSULIN; LEPTIN RECEPTOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FEMALE; GENOTYPE; GLOMERULUS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; MALE; MORTALITY; MOUSE; NONHUMAN; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEINURIA; STREPTOZOCIN DIABETES; ZYMOGRAPHY;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; FEMALE; KIDNEY; MALE; MICE; MICE, INBRED STRAINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; URINARY PLASMINOGEN ACTIVATOR;

EID: 33747212754     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093673     Document Type: Article

References (55)

1. Collins A, Kasiske B, Herzog C, et al: Excerpts from the United States Renal Data System's 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45:v-vii.
2. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-1666.
3. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-268.
4. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108:1853-1863.
5. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75.
6. Abouna GM, Al-Adnani MS, Kremer GD, Kumar SA, Daddah SK, Kusma G: Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients. Lancet 1983;ii:1274-1276.
7. Eddy AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-F220.
8. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001;60:587-596.
9. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 2003;14:1254-1271.
10. Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgamer RE, Peters MA, Zhang G, Eddy AA: Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005;67:2221-2238.
11. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, Grino M, Juhan-Vague I, Alessi MC: Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002;22:173-178.
12. Yamamoto K, Takeshita K, Shimokawa T, Yi H, Isobe K, Loskutoff DJ, Saito H: Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci USA 2002;99:890-895.
13. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Dano K: Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 1987;6:1281-1286.
14. Sawdey MS, Loskutoff DJ: Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha and transforming growth factor-beta. J Clin Invest 1991;88:1346-1353.
15. Pandey M, Tuncman G, Hotamisligil GS, Samad F: Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1. Am J Pathol 2003;162:933-941.
16. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993;13:1822-1828.
17. James LR, Fantus IG, Goldberg H, Ly H, Scholey JW: Overexpression of GFAT activates PAI-1 promoter in mesangial cells. Am J Physiol Renal Physiol 2000;279:F718-F727.
18. Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperin-sulinemic states. Proc Natl Acad Sci USA 1991;88:9959-9963.
19. Dichtl W, Stiko A, Eriksson P, Goncalves I, Calara F, Banfi C, Ares MP, Hamsten A, Nilsson J: Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:3025-3032.
20. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M: Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000;97:12222-12226.
21. Vulin AI, Stanley FM: Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem 2004;279:25172-25178.
22. Uchida Y, Ohba K, Yoshioka T, Irie K, Muraki T, Maru Y: Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway. J Biol Chem 2004;279:4075-4083.
23. Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107:398-404.
24. Gurlek A, Bayraktar M, Kirazli S: Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels. Diabetes Care 2000;23:88-92.
25. Mansfield MW: Increased plasma plasminogen activator inhibitor 1 in relatives of type 2 diabetic patients. Diabetes Care 2000;23:1035-1037.
26. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-1137.
27. Hirano T, Kashiwazaki K, Moritomo Y, Nagano S, Adachi M: Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res Clin Pract 1997;36:11-18.
28. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
29. Schleiffer T, Hellstern P, Freitag M, Brass H: Plasminogen activator inhibitor-1 activity and lipoprotein(a) in nephropathic patients with non-insulin-dependent diabetes mellitus versus patients with nondiabetic nephropathy. Haemostasis 1994;24:49-54.
30. Hovind P, Tarnow L, Rossing P, Teerlink T, Stehouwer CD, Emeis JJ, Parving HH: Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 2001;38:1376-1380.
31. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996;49:461-469.
32. Paueksakon P, Revelo MP, Ma LJ, Marcantoni C, Fogo AB: Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 2002;61:2142-2148.
33. Hagiwara H, Kaizu K, Uriu K, Noguchi T, Takagi I, Qie YL, Seki T, Ariga T: Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Thromb Res 2003;111:301-309.
34. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005;67:1297-1307.
35. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-495.
36. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ: Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999;96:6902-6907.
37. Samad F, Loskutoff DJ: The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemost 1997;78:652-655.
38. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993;92:2746-2755.
39. Kunjathoor VV, Wilson DL, LeBoeuf RC: Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996;97:1767-1773.
40. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, Couser WG, Alpers CE: Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003;14:968-980.
41. Kivirikko KI, Laitinen O, Prockop DJ: Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 1967;19:249-255.
42. Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ: Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001;15:1840-1842.
43. Brown JA, Chua SC Jr, Liu SM, Andrews MT, Vandenbergh JG: Spontaneous mutation in the db gene results in obesity and diabetes in CD-1 outbred mice. Am J Physiol Regul Integr Comp Physiol 2000;278:R320-R330.
44. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-160.
45. Hattori N, Mizuno S, Yoshida Y, Chin K, Mishima M, Sisson TH, Simon RH, Nakamura T, Miyake M: The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 2004;164:1091-1098.
46. Mizuno S, Nakamura T: Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 2004;286:F134-F143.
47. Brown PA, Wilson HM, Reid FJ, Booth NA, Simpson JG, Morrison L, Power DA, Haites NE: Urokinase-plasminogen activator is synthesized in vitro by human glomerular epithelial cells but not by mesangial cells. Kidney Int 1994;45:43-47.
48. Rondeau E, Ochi S, Lacave R, He CJ, Medcalf R, Delarue F, Sraer JD: Urokinase synthesis and binding by glomerular epithelial cells in culture. Kidney Int 1989;36:593-600.
49. Xu Y, Berrou J, Chen X, Fouqueray B, Callard P, Sraer JD, Rondeau E: Induction of urokinase receptor expression in nephrotoxic nephritis. Exp Nephrol 2001;9:397-404.
50. Benzing T: Signaling at the slit diaphragm. J Am Soc Nephrol 2004;15:1382-1391.
51. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, Honey K, Ishidoh K, Kominami E, Kreidberg JA, Tomino Y, Mundel P: Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and a3 integrin. J Biol Chem 2004;279:34827-34832.
52. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG: Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell 2001;12:1467-1479.
53. 3 Matsuo S, López-Guisa J, Cai X, Okamura D, Alpers C, Bumgarner C, Peters M, Zhang Z, Eddy A: Multi-functionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1 over-expressing mice. Kidney Int 2005;67.
54. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor-1. Diabetes 2004;53:336-346.
55. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I: Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000;20:1150-1154.